Autolus Therapeutics PLC
NASDAQ:AUTL
Income Statement
Earnings Waterfall
Autolus Therapeutics PLC
Revenue
|
10.5m
USD
|
Operating Expenses
|
-185.5m
USD
|
Operating Income
|
-175m
USD
|
Other Expenses
|
-46.3m
USD
|
Net Income
|
-221.3m
USD
|
Income Statement
Autolus Therapeutics PLC
Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||
Revenue |
3
N/A
|
1
-56%
|
1
-4%
|
2
+31%
|
2
+6%
|
2
-5%
|
3
+83%
|
3
-15%
|
2
-9%
|
2
-4%
|
1
-74%
|
3
+361%
|
6
+134%
|
7
+18%
|
7
N/A
|
6
-26%
|
2
-69%
|
11
+518%
|
|
Operating Income | |||||||||||||||||||
Operating Expenses |
(145)
|
(156)
|
(158)
|
(166)
|
(170)
|
(170)
|
(170)
|
(167)
|
(167)
|
(169)
|
(176)
|
(182)
|
(174)
|
(173)
|
(174)
|
(176)
|
(177)
|
(185)
|
|
Selling, General & Administrative |
(44)
|
(41)
|
(37)
|
(37)
|
(41)
|
(36)
|
(35)
|
(33)
|
(38)
|
(32)
|
(33)
|
(33)
|
(37)
|
(33)
|
(36)
|
(38)
|
(55)
|
(56)
|
|
Research & Development |
(101)
|
(111)
|
(117)
|
(124)
|
(128)
|
(134)
|
(135)
|
(134)
|
(129)
|
(137)
|
(143)
|
(148)
|
(137)
|
(139)
|
(138)
|
(138)
|
(122)
|
(130)
|
|
Other Operating Expenses |
0
|
(4)
|
(4)
|
(4)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(142)
N/A
|
(154)
-9%
|
(157)
-2%
|
(164)
-5%
|
(168)
-3%
|
(169)
0%
|
(167)
+1%
|
(165)
+1%
|
(164)
+0%
|
(167)
-2%
|
(176)
-5%
|
(179)
-2%
|
(168)
+6%
|
(165)
+1%
|
(166)
-1%
|
(170)
-2%
|
(176)
-3%
|
(175)
+0%
|
|
Pre-Tax Income | |||||||||||||||||||
Interest Income Expense |
3
|
3
|
1
|
1
|
1
|
(1)
|
(3)
|
(2)
|
(3)
|
(3)
|
(3)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(29)
|
(40)
|
|
Non-Reccuring Items |
(4)
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
(1)
|
(4)
|
(4)
|
(5)
|
(4)
|
(0)
|
|
Total Other Income |
5
|
10
|
6
|
0
|
1
|
(1)
|
(2)
|
1
|
2
|
0
|
(1)
|
(5)
|
0
|
0
|
2
|
4
|
0
|
(2)
|
|
Pre-Tax Income |
(139)
N/A
|
(142)
-2%
|
(149)
-5%
|
(163)
-9%
|
(166)
-2%
|
(172)
-3%
|
(172)
0%
|
(166)
+3%
|
(166)
+0%
|
(170)
-2%
|
(180)
-6%
|
(189)
-5%
|
(173)
+8%
|
(174)
-1%
|
(174)
+0%
|
(176)
-1%
|
(208)
-19%
|
(217)
-4%
|
|
Net Income | |||||||||||||||||||
Tax Provision |
15
|
15
|
19
|
22
|
24
|
26
|
26
|
23
|
24
|
24
|
25
|
26
|
24
|
23
|
19
|
18
|
0
|
(4)
|
|
Income from Continuing Operations |
(124)
|
(127)
|
(130)
|
(140)
|
(142)
|
(146)
|
(147)
|
(143)
|
(142)
|
(146)
|
(155)
|
(164)
|
(149)
|
(152)
|
(155)
|
(158)
|
(208)
|
(221)
|
|
Net Income (Common) |
(124)
N/A
|
(127)
-2%
|
(130)
-3%
|
(140)
-8%
|
(142)
-1%
|
(146)
-2%
|
(147)
-1%
|
(143)
+2%
|
(142)
+1%
|
(146)
-3%
|
(155)
-6%
|
(164)
-6%
|
(149)
+9%
|
(152)
-2%
|
(155)
-2%
|
(158)
-2%
|
(208)
-32%
|
(221)
-6%
|
|
EPS (Diluted) |
-2.88
N/A
|
-2.53
+12%
|
-2.5
+1%
|
-2.69
-8%
|
-2.76
-3%
|
-2.32
+16%
|
-2.07
+11%
|
-1.96
+5%
|
-1.97
-1%
|
-1.6
+19%
|
-1.7
-6%
|
-1.79
-5%
|
-1.57
+12%
|
-0.87
+45%
|
-0.89
-2%
|
-0.9
-1%
|
-1.2
-33%
|
-0.99
+18%
|